Treatment and disease management practices in patients with MPNs in 6 countries: an expansion of the MPN LANDMARK survey

In a multicountry, cross-sectional survey of disease management practices as reported in an expansion of the MPN LANDMARK survey in China, Turkey, Russia, Taiwan, South Korea, and Saudi Arabia, researchers found a lack of urgency in treating MPN patients—with approximately 18-24% of physicians reporting that the observe patients instead of recommending drug treatment. The analysis, which was presented during the virtual 2020 European Hematology Association Annual Congress, also found that when they did begin treatment, most physicians use hydroxyurea for patients with MPNs in spite of other available options.